Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Menorrhagia 1Leiomyoma 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × elagolix × Clear all
NCT03886220 2022-03-31

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

AbbVie

Phase 4 Completed
82 enrolled 10 charts

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡